Gross G
Klinik und Poliklinik für Dermatologie und Venerologie, Universitätsklinikum AöR, Universität Rostock, Augustenstrasse 80-84, 18055 Rostock, Deutschland.
Hautarzt. 2007 Jun;58(6):507-14. doi: 10.1007/s00105-007-1349-2.
Prophylactic HPV L1 VLP quadrivalent and bivalent vaccines are of great importance for patients seen by dermatologists and venereologists. Both vaccines protect against HPV16- and HPV18-associated anogenital cancers, as well as cancers of the mouth, the upper respiratory tract and skin, especially of the fingers and periungual region. The quadrivalent HPV6, 11, 16, 18 vaccine also prevents anogenital warts (condylomata acuminata) which are the most common benign tumors of this body region. HPV-vaccination (Gardasil) has been approved in Germany since October 2006 for young girls between 9-16 and young women between 16-26 years of age. Many experts feel that boys and young men should also be vaccinated. Men would profit from a vaccine that protects against HPV infections, especially anogenital warts, as well as penile and anal carcinomas. In immunosuppressed organ transplant recipients and HIV-positive individuals, HPV can be widespread, chronic and often rapidly progressive to malignant tumors; thus these groups would greatly benefit from HPV immunization.
预防性人乳头瘤病毒1型主要衣壳蛋白（HPV L1）病毒样颗粒四价和二价疫苗对皮肤科医生和性病科医生诊治的患者非常重要。这两种疫苗都可预防与HPV16和HPV18相关的肛门生殖器癌以及口腔、上呼吸道和皮肤癌，尤其是手指和甲周区域的癌症。四价HPV6、11、16、18疫苗还可预防肛门生殖器疣（尖锐湿疣），这是该身体部位最常见的良性肿瘤。自2006年10月起，HPV疫苗（加德西）在德国已被批准用于9至16岁的年轻女孩和16至26岁的年轻女性。许多专家认为男孩和年轻男性也应接种疫苗。男性将受益于一种可预防HPV感染的疫苗，尤其是肛门生殖器疣以及阴茎癌和肛门癌。在免疫抑制的器官移植受者和HIV阳性个体中，HPV可能广泛存在、呈慢性且往往迅速进展为恶性肿瘤；因此，这些人群将从HPV免疫接种中大大受益。
